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Objective: To examine if angiotensin converting enzyme inhibitor reduces the risk of pneumonia in older
patients on tube-feeding because of dysphagia from cerebrovascular diseases.
Design: Randomized placebo-controlled trial.
Setting: Acute and subacute geriatrics units, speech therapists’ clinic, and nursing home.
Participants: Older patients on tube-feeding for >2 weeks because of dysphagia secondary to cerebro-
vascular diseases.
Intervention: Participants were randomized to lisinopril 2.5 mg or placebo once daily for 26 weeks.
Measurements: Participants were followed up at weeks 12 and 26. The primary outcome was the inci-
dence rate of pneumonia as determined by pneumonic changes on x-ray and clinical criteria. The sec-
ondary outcomes were mortality rate and swallowing ability as deﬁned by the Royal Brisbane Hospital
Outcome Measure for Swallowing at week 12.
Results: A total of 93 older patients were randomized. In interim analysis, 71 completed the trial, whereas
15 had dropped out. Among those who had completed the trial, odds ratio (OR) for death was signiﬁcantly
higher in the intervention group (unadjusted OR 2.94, P¼ .030; fully adjusted OR 7.79, P¼ .018). There was
no difference in the incidence of pneumonia or fatal pneumonia in the 2 groups. The intervention group
had a marginally better swallowing function at week 12 (Royal Brisbane Hospital Outcome Measure for
Swallowing score: 4.2  1.5 in intervention group, 3.5  1.5 in placebo group, P ¼ .053). As a result of the
interim ﬁnding on mortality, the trial was prematurely terminated with 7 participants still in the trial.
Conclusions: Low dose lisinopril given to older tube-fed patients with neurologic dysphagia resulted in
increased mortality, although swallowing function showed marginal improvement. ACE inhibitors did
not prevent pneumonia in older patients with neurologic dysphagia and might increase mortality.
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J.S.W. Lee et al. / JAMDA 16 (2015) 702e707 703Tube feeding is increasingly used in frail older people with
dysphagia for the prevention of aspiration pneumonia and the
Dysphagia Assessmentmaintenance of nutrition. This practice is particularly common in
nursing home settings. However, despite tube-feeding, these patients
still have high recurrence rates of pneumonia resulting in hospitali-
zations and mortality. Contrary to common belief, there is no evi-
dence that tube-feeding prevents aspiration pneumonia in patients
with dysphagia.1
Angiotensin enzyme converting (ACE) inhibitor is a commonly
used antihypertensive drug that can cause a dry cough as a side effect.
One of the mechanisms for this side effect is the decreased degra-
dation of substance P, which is released from sensory nerve terminals
in the nasopharynx. It has been found that substance P level in
sputum is low in aspiration pneumonia patients.2 Previous random-
ized trials have shown that ACE inhibitor could signiﬁcantly improve
swallowing reﬂex and reduce silent aspirations without lowering
blood pressure in at-risk patients.3,4 Observational studies have also
found that ACE inhibitor use was associated with lower incidence of
pneumonia in older stroke patients with hypertension.5 A meta-
analysis found that ACE inhibitor may have a protective role in
pneumonia, especially in stroke patients and among Asian popula-
tions.6,7 ACE inhibitors may, therefore, have a role in preventing
pneumonia in frail patients with dysphagia by improving their
swallowing and cough reﬂexes. Two recent case-control studies,
however, have failed to ﬁnd any association between ACE inhibitor
use and pneumonia among a general Asian population8 and in the
older general population.9 Its effect in patients with very high risk of
aspirations and pneumonia were yet uncertain.
We hypothesized that ACE inhibitors may reduce the incidence of
pneumonia in tube-fed patients with neurologic dysphagia related to
cerebrovascular disease and conducted a randomized controlled trial
(RCT) to examine the effectiveness and safety of an ACE inhibitor in
preventing pneumonia in this high-risk group of patients. A lower
dose was used because of the risk of hypotension and electrolyte
disturbances with ACE inhibitors in frail older people.Methods
Participants
Tube-fed patients aged 60 years or older were recruited from the
medical wards of an acute university, 2 subacute hospitals, afﬁliated
geriatric outpatient clinics, and speech therapy clinics in Hong Kong.
All had a history of recent hospitalization in the previous 3 months.
They had been on tube-feeding for more than 2 weeks because of
neurologic dysphagia as recommended by a trained speech therapist.
The clinical diagnosis of cerebrovascular diseases was conﬁrmed by
computerized axial tomography of the brain. Exclusion criteria
included the following: life expectancy less than 6 months, baseline
systolic blood pressure less than 100 mm Hg, known intolerance to
ACE inhibitors, current use of ACE inhibitor or angiotensin receptor
blockers, symptomatic chronic lung disease or cardiac failure,
frequent withdrawal of enteral tube by patients, serum creatinine
>150 mmol/L, and serum potassium >5.1 mmol/L. The study was
approved by the combined Ethics Committee of the Hospital
Authority New Territories East Cluster and the Chinese University of
Hong Kong. It was registered in ClinicalTrials.gov under the trial
number of NCT02358642.Measurements
After obtaining written informed consent from participants or
family caregivers (if participants were incapable of giving informed
consent), the following measurements were made.All participants were assessed by designated speech therapists
who rated the participants’ swallowing ability by the Royal Brisbane
Hospital Outcome Measure for Swallowing (RBHOMS).10 It is a clini-
cally assessment scale for swallowing ability graded from levels of 1
to 10. Stage A comprises of level 1e3 and indicates the need to be
kept nil by mouth; stage B comprises of level 4 and indicates ﬁtness
for commencing oral intake; stage C comprises of levels 5e7 and
indicates the establishment of oral intake; and stage D comprises of
levels 8e10 and indicates maintaining oral intake.
Demographics
Information regarding the following were collected: place of
residence (home or nursing home), history of medical diseases
(including history and time of stroke, history of recent pneumonia in
recent hospitalization, diabetes, hypertension, dementia, Parkinson
disease, chronic obstructive pulmonary diseases, and congestive
heart failure), and concurrent use of antihypertensives. Duration of
dysphagia and tube-feeding, information about the formula, and
feeding regime were also recorded.
Blood Tests and Clinical Characteristics
All participants had a nonfasting blood test for baseline renal
function prior to the start of the trial. Another renal function test was
performed within 1 week after the start of the trial to ensure toler-
ance to the study drug.
On the day prior to the start of the trial, sitting blood pressure at
rest was taken on 2 consecutive occasions, and the average was used
for analysis. Mid-arm circumference was measured to estimate
nutritional status.11 Modiﬁed Barthel index was used to measure
basic functional status (maximum score of 20).12 Abbreviated mental
test score was administered to screen for dementia.13 A local valida-
tion study showed that cut-off values of 4 and 6 out of 10 in illiterate
and educated people respectively suggested dementia.
Intervention
The intervention group participants were given lisinopril 2.5 mg
once daily at bedtime. A low dose regime was chosen as it was less
likely to cause hypotension, electrolyte disturbances, and impair
renal function. A similar low dose ACE inhibitor regime had been
shown to be effective in preventing silent aspiration.4 The control
group participants were given identical placebo once daily at
bedtime.
Randomization
Participants were randomized according to a computer-generated
random sequence. The manufacturer of the trial tablets was respon-
sible for generating the group assignment and packaged the drug
bottles accordingly. Consecutive participants were assigned a partic-
ipant number. They were given 4 weekly supplies of trial drugs in
bottles labeled by their participant numbers. The coding ﬁle was kept
by the manufacturer and a research assistant not involved in the trial.
The coding was kept conﬁdential to all other parties until the end of
the trial.
Safety Monitoring
Sitting blood pressure was measured at least 3 times in the ﬁrst
24 hours after the ﬁrst dose of trial drug in all participants. Blood
pressure was measured at week 12 follow-up. Renal function test was
Fig. 1. Study design and participants.
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pants who had a systolic blood pressure drop to below 100 mm Hg,
elevated serum potassium (>5.1 mmol/L), and worsening of renal
function after the ﬁrst dose of the trial drug would be discontinued
for the trial.
Outcome Measures
The primary outcome was the incidence rate of pneumonia within
the 26-week trial period. The secondary outcomes were mortality
rate at week 26 and RBHOMS score at week 12.
Incidence of Pneumonia
All hospital admissions to public hospitals during the trial period
were traced by the clinical management system of the Hospital
Authority computer database. The discharge summaries were scru-
tinized by a physician and a respiratory physician not involved in the
project for the diagnosis of pneumonia on hospital admission and
during hospital stay. The criteria for pneumonia were as follows: the
presence of new pneumonic changes in the chest x-ray (done in index
admission used for reference) and 1 major clinical sign: increased
sputum production or 2 of the following minor clinical signs: raisedor depressed white cell count, hypoxia at room air (SpO2 <92%) and
tympanic temperature greater than 38

C. If the participants were
admitted to a private hospital or treated in the community for rea-
sons of fever, cough, or breathlessness, a questionnaire was sent to
the attending doctor for the above speciﬁc symptoms and signs of
pneumonia. Based on that, the physician would determine whether
pneumonia had occurred. The physician was blinded to group
assignment.
Mortality
Survival status was ascertained from the Clinical Management
System of the Hospital Authority or the death registry if necessary.
The Clinical Management System is a computerized system that
captures clinical and laboratory data in the public hospitals and
clinics in Hong Kong.
Swallowing Function
Swallowing function was re-assessed by a speech therapist at
week 12, and the degree of dysphagia was recorded as the RBHOMS
score as at the baseline. Further swallowing follow-up would be
arranged at the discretion of the speech therapist.
Table 1
Comparison of Baseline Characteristics of Intervention and Placebo Groups (N ¼ 71)
Variables Intervention
(N ¼ 33)
Placebo
(N ¼ 38)
P Value
Demographic
Age (year) 83.4 (6.8) 84.4 (5.6) NS
Female (n, %) 25 (75.8) 25 (65.8) NS
Nursing home resident (n, %) 29 (87.9) 30 (81.1) NS
Functional, nutritional, and biochemical indices
Modiﬁed BI score 1.1 (3.6) 0.9 (3.5) NS
AMT score 1.1 (2.6) 0.3 (1.2) NS
RBHOMS score 3.1 (0.8) 2.9 (0.7) NS
Tube fed volume per feed (mL) 216.6 (80.5) 226.7 (54.3) NS
Serum albumin (g/L) 29.7 (4.9) 31.4 (5.7) NS
Mean mid arm circumference (cm) 22.2 (3.1) 22.4 (3.0) NS
Serum potassium (mmol/L) 4.1 (0.5) 4.2 (0.4) NS
Serum creatinine (mmol/L) 66.6 (21.4) 73.1 (39.6) NS
Mean systolic blood pressure (mm Hg) 130.4 (15.8) 128.4 (16.2) NS
Mean diastolic blood pressure (mm Hg) 70.7 (12.1) 69.1 (7.6) NS
Mean systolic blood pressure 12 hours
after ﬁrst dose (mmHg)
122.3 (17.3) 123.5 (14.1) NS
Mean diastolic blood pressure 12 hours
after ﬁrst dose (mmHg)
65.7 (13.7) 66.9 (8.8) NS
Medical Conditions
Stroke (n, %) 32 (100) 36 (94.7) NS
Diabetes mellitus (n, %) 5 (15.2) 10 (26.3) NS
Hypertension (n, %) 22 (66.7) 32 (84.2) NS
Dementia (n, %) 17 (51.5) 20 (52.6) NS
Parkinson disease (n, %) 3 (9.1) 3 (7.9) NS
Chronic obstructive pulmonary
diseases (n, %)
1 (3.0) 1 (2.6) NS
Heart failure (n, %) 0 (0.0) 1 (2.6) NS
New stroke on current admission (n, %) 2 (6.1) 8 (21.1) NS
Pneumonia in current admission (n, %) 19 (57.6) 26 (68.4) NS
AMT, abbreviated mental test; modiﬁed BI, modiﬁed Barthel Index; NS, not signif-
icant; SD, standard deviation.
All values expressed as mean (SD) unless otherwise indicated.
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Based on a local randomized trial in which 33% of older tube-fed
patients with previous stroke developed pneumonia within
6 months posthospital discharge, a group sample size of 80 had an
80% power in detecting a 58% relative risk reduction in the incidence
of pneumonia requiring hospital admission at P < .05. Allowing for
20% dropout rate, the total sample size was estimated to be 200.
Statistical Analysis
Statistical analysis was performed using SPSS v 22.0 (SPSS Inc,
Chicago, IL). Group comparison was made by c2 and Student t tests
for categorical and continuous variables, respectively. Logistic
regressions were used to examine the effects of lisinopril on the
clinical outcomes with and without adjustments for relevant cov-
ariates. A P value of <.05 was taken as statistical signiﬁcance. Owing
to the ﬁnding at interim analysis that the intervention group had
signiﬁcantly higher all-cause mortality, the study was terminated
prematurely. At the time of termination, 7 participants (3 in placebo
group, 4 in intervention group) were still undergoing the study, whileTable 2
Odds Ratio of Clinical Outcomes in the Intervention Group Compared With the Placebo
Outcomes Unadjusted OR (95% CI) P Value Age-Adjus
Pneumonia 1.51 (0.59, 3.86) .391 1.58 (0.61,
Death 2.94 (1.11, 7.77) .030 3.65 (1.28,
Fatal pneumonia 2.06 (0.76, 5.60) .155 2.18 (0.79,
Pneumonia or death 1.80 (0.69, 4.72) .232 2.06 (0.75,
Fully-adjusted model: adjusted for age, gender, admission for pneumonia in current episo
diabetes, chronic obstructive airway disease, and heart failure.
Note: Bold font indicates statistical signiﬁcance (P < .05).71 participants had completed the study (reached end of 6 months or
death, whichever occurred earlier). Only data from patients who had
completed the study were analyzed.
Results
From October 2009 to October 2012, 93 participants had been
recruited and randomized (Figure 1). The characteristics of the par-
ticipants who had completed the study are shown in Table 1. None of
the baseline characteristics were signiﬁcantly different between the
groups. Neither was the mean blood pressures measured 12 hours
after the ﬁrst dose of study drug administration signiﬁcantly different
among the participants of the 2 groups.
The comparison of the odds ratio (OR) of clinical outcomes bet-
ween the trial groups was shown in Table 2. Treatment group par-
ticipants had signiﬁcantly higher adjusted 6-month mortality (OR
7.79, P ¼ .018) and rate of composite endpoint (pneumonia or death)
(OR 7.16, P ¼ .025). The incidences of pneumonia and fatal pneumonia
(pneumonia-related death) were not signiﬁcantly different between
the groups (57.6% in intervention group vs 47.4% in placebo group, c2
test P ¼ .390; 42.4% in intervention group vs 26.3% in placebo group,
c2 test P ¼ .152, respectively).
In multiple regression analysis, age (OR 1.17 per year increment,
P ¼ .044, 95% CI 1.00, 1.37) and albumin at baseline (OR 0.76 per g/L
increment, P ¼ .017, 95% CI 0.60, 0.95) were additional factors
signiﬁcantly associated with 6-month mortality. Baseline RBHOMS
score was the only factor signiﬁcantly associated with pneumonia
within 6 months (OR 0.18 per additional score, P ¼ .014, 95% CI
0.05, 0.71).
Twenty treatment group participants and 28 placebo group par-
ticipants had repeat swallowing assessment at week 12. Comparisons
of their swallowing function at baseline and at week 12 were shown
in Table 3. There was no difference in their mean RBHOMS scores at
baseline. At week 12, although the difference was still statistically
insigniﬁcant, there was a trend toward higher scores in the inter-
vention group participants (P ¼ .053). Table 4 showed the causes of
death of participants. Majority of deaths were due to pneumonia.
There were no signiﬁcant differences in the number of any speciﬁc
cause of death between the groups.
Discussion
Our results showed that low dose lisinopril did not lower the
incidence of pneumonia in older patients on tube-feeding because of
neurologic dysphagia. The incidence of pneumonia was similarly high
in both trial groups. This is in contrast with previous reports of
reduced pneumonia incidence in stroke patients treated with ACE
inhibitors.5,6 A possible reason for this difference in ﬁndings might be
that our participants had a much higher risk of pneumonia than those
in the other studies, owing to the use of tube-feeding and having
more severe dysphagia. In addition, the dose of ACE inhibitor used in
this trial was lower than what stroke patients would usually receive.
To our knowledge, this was the ﬁrst randomized controlled study
to examine the effect of an ACE inhibitor on pneumonia in olderGroup
ted OR (95% CI) P Value Fully-Adjusted OR (95% CI) P Value
4.09) .346 4.07 (0.87, 19.15) .076
10.43) .016 7.79 (1.42, 42.65) .018
6.01) .132 2.54 (0.53, 12.16) .243
5.67) .161 7.16 (1.28, 40.10) .025
de, RBHOMS score, modiﬁed BI, baseline serum creatinine, baseline serum albumin,
Table 3
Comparison of Swallowing Function in Participants
RBHOMS Score Intervention Group
(N ¼ 33)
Placebo Group
(N ¼ 38)
P Value*
Baseline 3.7 (0.8)
N ¼ 29
2.9 (0.7)
N ¼ 35
.462
At week 12 4.2 (1.5)
N ¼ 20
3.5 (1.5)
N ¼ 28
.053
SD, standard deviation.
Data presented as mean (SD).
*Comparison done by Mann-Whitney U test.
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Previous studies were largely observational studies in general popu-
lations or community-living elderly cohorts,5,14 whereas RCTs quoted
in a recent meta-analysis were secondary analysis of larger RCTs with
nonpneumonia primary outcomes.6 Both the differences in study
methods and the characteristics of the participants could account for
the difference in ﬁndings: the participants in our study were much
more frail than those participating in medication RCTs, and had a
much higher risk of pneumonia because of their severity of
dysphagia. The presence of tube-feeding would in fact have further
increased the risk of aspiration pneumonia,1 making our study par-
ticipants a very high-risk group. Although in theory any effect of an
intervention should be most easily detected in the group with the
highest risk, our results had shown the contrary. The unexpectedly
high mortality rate in the study (40.8% within 6 months) had led to an
interim analysis, resulting in the premature termination of the study
because of ethical reasons.
We found a signiﬁcantly higher mortality rate among the inter-
vention group participants. The increase in mortality appeared to be
attributed to a higher number of pneumonia deaths (n ¼ 14, 42.4% in
entire intervention group vs n ¼ 7, 18.4% in entire placebo group), as
the number of nonpneumonia deaths were similar (n ¼ 3 in placebo
group vs n ¼ 5 in intervention group). However, the proportions of
deaths because of pneumonia were similar in both groups (70% in
placebo group vs 73% in intervention group). In addition, comparison
of fatal pneumonia did not reach statistical signiﬁcance in multiple
logistic regression analysis. Detailed study of the case records of fatal
pneumonia episodes in the treatment group did not suggest an
important role of hypotension or electrolyte disturbances. Clinicians
were free to stop trial drugs as clinically indicated. Therefore, this
increase in absolute number of pneumonia deaths might have been a
chance ﬁnding in group of very frail participants, who were suscep-
tible to infective as well as aspiration pneumonia. Nonetheless, our
results suggested that using ACE inhibitors as a means to prevent
pneumonia was not beneﬁcial to these frail high-risk patients. In fact,
there is little evidence that medications or feeding methods could
alter the course of aspirations or pneumonia in this group of patients.
In earlier cohorts, tube-feeding was not associated with reduction in
aspiration pneumonia.1 Likewise, in an earlier RCT, pump feeding had
also failed to reduce the incidence of pneumonia by virtue of slower
formula infusion into the stomach.15Table 4
Causes of Death Among Study Participants
Placebo (N ¼ 38) Intervention (N ¼ 33)
Number of deaths within group 10 (26.3) 19 (57.6)
Pneumonia 7 (18.4) 14 (42.4)
Urosepsis 2 (5.3) 0 (0.0)
Ischemic heart disease 1 (2.6) 0 (0.0)
Pulmonary embolism 0 (0.0) 1 (3.0)
Cancer of skin 0 (0.0) 1 (3.0)
Sudden death 0 (0.0) 2 (6.0)
Aspiration after vomiting 0 (0.0) 1 (3.0)
Numbers are represented as n (% of total participants within group).There was a trend toward better swallowing function in the
intervention group at week 12. This was consistent with the ﬁndings
of previous trials that suggested ACE inhibitors improved swallowing
function.3,4 However, the very high mortality of the participants,
possibly attributable to their frail physical state, would have offset
any potential beneﬁt of ACE inhibitors in the prevention of pneu-
monia or the improvement in swallowing function. In fact, 27.6% of
the deaths were not due to pneumonia, while the pneumonia rate
was not signiﬁcantly different between the groups. Further trials to
examine the potential effects of ACE inhibitors on swallowing func-
tion in a more stable patient group are warranted.
ACE inhibitors have been shown to have immune-modulating
effects.16 Although these may have beneﬁcial effects in autoimmu-
nity, the impact of these effects in acute severe infection is not
known. Although observational studies in community-based popu-
lations suggested a protective or nonsigniﬁcant effect of ACE
inhibitors in pneumonia,6,14,17 our results showed that whatever
immune-modulating effects ACE inhibitors might have did not
beneﬁt these very frail participants.Limitations
Our study participants were a selective group of physically frail
older patients with severe dysphagia and in situ feeding tube, the
ﬁndings would be unlikely to be generalizable to the general popu-
lation, or to a more stable patient group with dysphagia. The dose of
lisinopril used in the study was much lower than the usual dose used
in treatment of hypertension, congestive heart failure, or micro-
albuminuria in diabetes mellitus. It was uncertain whether a higher
dose would have a more prominent effect in terms of pneumonia
reduction. A large cohort study had reported a dose-effect relation-
ship among diabetic patients.18 In concordance with other studies,2e5
we did ﬁnd an insigniﬁcant improvement in swallowing function
after 3 months of low dose lisinopril. However, the small number of
participants undergoing swallowing assessment precluded a deﬁnite
conclusion about the clinical signiﬁcance of this marginal improve-
ment. It did not affect the pneumonia or pneumonia-related death
outcomes in this study. Given that poorer swallowing function
assessed by the RBHOMS score was a signiﬁcant predictor of pneu-
monia in this study, a larger RCT with swallowing function as an
outcome would be required to answer that question.Conclusions
We could not ﬁnd evidence that ACE inhibitors could reduce the
incidence of pneumonia in older tube-fed patients with neurologic
dysphagia because of cerebrovascular disease. Although swallowing
function marginally improved, there was a suggestion of an increase
in mortality with the introduction of lisinopril in these high-risk
patients.Acknowledgments
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